Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

We recently compiled a list of the 10 Trending AI Stocks on Wall Street’s Radar. In this article, we are going to take a look ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...

Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

H.C. Wainwright has recently reiterated BigBear.ai Holdings Inc (BBAI) stock to Buy rating, as announced on December 30, 2024, according to Finviz. Earlier, on January 9, 2024, Cantor Fitzgerald had ...

Morgan Stanley cut shares of Adagene (NASDAQ:ADAG – Free Report) from an overweight rating to an equal weight rating in a report published on Friday morning, MarketBeat reports. Separately, HC ...